Outcomes of the two generations of bioresorbable scaffolds (Magmaris vs. Absorb) in acute coronary syndrome in routine clinical practice
| Autor: | Piotr, Rola, Adrian, Włodarczak, Magdalena, Łanocha, Mateusz, Barycki, Marek, Szudrowicz, Jan J, Kulczycki, Joanna, Jaroszewska-Pozorska, Alicja, Gosiewska, Katarzyna, Woźnica, Maciej, Lesiak, Adrian, Doroszko |
|---|---|
| Rok vydání: | 2022 |
| Předmět: | |
| Zdroj: | Cardiology Journal. |
| ISSN: | 1898-018X 1897-5593 |
| DOI: | 10.5603/cj.a2022.0047 |
| Popis: | Acute coronary syndrome (ACS) as a clinical manifestation of coronary artery disease (CAD) remains a significant cause of mortality and morbidity, as reported worldwide annually. The second generation of drug-eluting stents (DES) is a gold standard in percutaneous interventions in ACS patients however, permanent caging of the vessel with metallic DES has some drawbacks. Bioresorbable vascular scaffolds (BRS) were designed as a temporal vessel-supporting technology allowing for anatomical and functional restoration. Nevertheless, following the initial encouraging reports, numerous concerns about the safety of BRS occurred.In this study, a 1-year performance of 193 patients with magnesium BRS - Magmaris (Biotronik, Berlin, Germany) was evaluated in comparison to 160 patients with polymer BRS - Absorb (Abbott-Vascular, Chicago, USA) in the non-ST-segment elevation-ACS setting.The Magmaris, when compared to Absorb showed a significantly lower rate of primary endpoint (death from cardiac causes, myocardial infarction, stent thrombosis) as well as target lesion failure in 30-day and 1 year follow-up. In the Absorb group, a significantly higher rate of stent thrombosis was observed.Data from the present study suggests encouraging safety a profile and more favorable clinical outcomes of Magnesium BRS in comparison to the polymer Absorb - BRS. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|